FDA approves generic lenacapavir for HIV prevention

The approval also gives public health groups a faster route to scale-up. Because FDA clearance often speeds regulatory review elsewhere, advocates say the shot could begin reaching some countries within weeks, though approval timelines will vary and funding remains a hurdle. The World Health Organization says 41 million people were living with HIV last year and 570,000 died from HIV-related causes.

For investors, the main market read-through is not U.S. sales — the generic cannot be sold there while Gilead Sciences’ branded Yeztugo remains protected by patent — but the pressure the move puts on the economics of HIV prevention globally. Gilead’s U.S. list price for Yeztugo is $28,218 a year, underscoring the gap between rich-country pricing and the low-cost supply now being built for poorer markets.

Gilead has already struck royalty-free licensing deals with six generic manufacturers, and the new FDA tentative approval, secured through a generic developed by India’s Dr. Reddy’s Laboratories with support from Unitaid, the Clinton Health Access Initiative and Wits RHI, should accelerate production. The company says those agreements provide the fastest and most sustainable way to broaden access.

The bigger story for the sector is policy and supply chain execution: if donors and governments fund procurement at scale, the drug could become a major tool in pushing down HIV incidence in the next few years. The immediate catalyst now shifts from regulatory clearance to national approvals, financing and distribution.